Oriva Therapeutics has appointed Agnès Arbat as CEO. Arbat will also serve as the company’s Chief Medical Officer.
Arbat brings more than 25 years of experience in the pharmaceutical industry, with a strong track record across clinical development, medical affairs and commercial strategy in women’s health.
She was previously Co-founder and CEO of Oxolife, a specialist biotech focused on female fertility. Prior to that, she led the Women’s Health and Cardiovascular medical team at Bayer and worked at Organon in Medical Affairs for Women’s Health.
Oriva Therapeutics is a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women.
Arbat said: “Oriva’s assets have the potential to deliver best-in-class treatments for women worldwide suffering from common, painful and debilitating gynaecological conditions – thus addressing clear and significant unmet medical needs.”
Clara Campàs, Co-Founder and Managing Partner at Asabys Partners, said: “Agnès’ deep scientific expertise in women’s health and her strong track record of strategic leadership makes her exceptionally well qualified to lead Oriva as it advances its programmes and accelerates through its next phase of growth.”